John Tsai, Forcefield Therapeutics CEO

Force­field Ther­a­peu­tics to start £35M Se­ries A in Oc­to­ber af­ter scoop­ing ex-No­var­tis ex­ec John Tsai as new CEO

For­mer No­var­tis chief med­ical of­fi­cer John Tsai is now a biotech CEO, and one of his first pri­or­i­ties at Lon­don, UK-based car­dio­vas­cu­lar biotech Force­field Ther­a­peu­tics will be to raise £35 mil­lion ($42 mil­lion) in a Se­ries A round.

“We’re plan­ning on kick­ing off the Se­ries A in the ear­ly part of Oc­to­ber… and we’re go­ing to give our­selves a win­dow of about four to six months to try to raise £35 mil­lion,” Tsai told End­points News in an in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.